Australia markets closed
  • ALL ORDS

    7,709.50
    +21.50 (+0.28%)
     
  • ASX 200

    7,493.80
    +25.50 (+0.34%)
     
  • AUD/USD

    0.7106
    -0.0011 (-0.16%)
     
  • OIL

    82.21
    +1.20 (+1.48%)
     
  • GOLD

    1,931.20
    +1.20 (+0.06%)
     
  • BTC-AUD

    32,305.25
    -368.92 (-1.13%)
     
  • CMC Crypto 200

    520.26
    -6.93 (-1.31%)
     
  • AUD/EUR

    0.6532
    +0.0003 (+0.05%)
     
  • AUD/NZD

    1.0966
    +0.0005 (+0.05%)
     
  • NZX 50

    12,036.05
    +12.59 (+0.10%)
     
  • NASDAQ

    12,051.48
    +236.79 (+2.00%)
     
  • FTSE

    7,770.89
    +9.78 (+0.13%)
     
  • Dow Jones

    33,949.41
    +205.57 (+0.61%)
     
  • DAX

    15,156.16
    +23.31 (+0.15%)
     
  • Hang Seng

    22,688.90
    +122.12 (+0.54%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     

Why Shares of Provention Bio Went Up 30.3% in November

Why Shares of Provention Bio Went Up 30.3% in November

Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.